Gaugene, a high-tech company dedicated to providing excellent hematological detection instruments, reagents and services for in vitro diagnostic users, will accelerate the commercialization and the rapid conversion of its innovative products with the fresh proceeds.
Gaugene (Chinese: 指真生物) completed the Series B round of financing worth more than CNY 100 million on 15 July. The round was led by Forture Capital (Chinese: 达晨财智), with the participation from Tao Capital (Chinese: 道远资本), Huihe Capital (Chinese: 惠合资本), Hybribio (Chinese: 凯普生物), Anbiping (Chinese: 安必平) and the existing investor Qiming Venture Partners (启明创投). Probe Capital (Chinese: 探针资本) continues to be the exclusive financial advisor for this round.
The funding will be used to accelerate the company's product market expansion, new technology and new product development.
Founded in 2017, Gaugene is a high-tech company which focuses on providing flow fluorescence multiplexed products for clinical diagnostics and life sciences research. Flow fluorescence detection is the new-generation high-throughput multi-testing platform, and it has become a newly emerged popular sector in in vitro diagnostics and life science research technology. The company's core products include five classification blood analyzer and flow cytometer.
Gaugene's competitors include Kindstar Global (Chinese: 康圣环球), Dirui (迪瑞医疗) and Mindray (Chinese: 迈瑞医疗).